Please assess the completion status of the following clinical trial:

Trial Title: Fludarabine or Observation in Treating Patients With Stage 0, Stage I, or Stage II Chronic Lymphocytic Leukemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Confirmed diagnosis of B-cell chronic lymphocytic leukemia~  * Rai stage 0-II (Binet stage A) disease~* Meets 1 of the following criteria:~  * High-risk disease, as defined by the following:~    * Serum thymidine kinase level \> 7.0 U/L~   * Elevated β2-microglobulin level~   * Presence of non-nodular bone marrow infiltration~   * Short lymphocyte doubling time~ * Low-risk disease~    * Meets none of the criteria (as listed above) for high-risk disease~PATIENT CHARACTERISTICS:~Performance status~* Not specified~Life expectancy~* More than 6 months~Hematopoietic~* No autoimmune hemolytic anemia~* No thrombocytopenia~Hepatic~* Not specified~Renal~* Not specified~Other~* No severe organ dysfunction~* No other prior or concurrent malignancy~PRIOR CONCURRENT THERAPY:~Chemotherapy~* No prior chemotherapy~* No other concurrent chemotherapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Fludarabine (Type: EXPERIMENTAL): None
- watch & wait (Type: NO_INTERVENTION): None

Based on this trial design, predict the completion outcome and termination type (if applicable).